Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Montréal

$28,000.00

3D Bioprinting of Cardiac Tissues

FY 2024-25

Summary
Chronic cardiovascular diseases such as heart failure is increasing to epidemic levels, affecting 1 in 5 Canadians. The left ventricle has no significant ability to regenerate and the viable tissue remaining after myocardial infarction is often insufficient to maintain adequate cardiac output. Heart transplant is very often not an available or appropriate option. Thus, there is a pressing need for alternative intervention. The long-term goal of this research program is to develop and utilize advanced biofabrication techniques integrated with insights from developmental biology to build engineered 3D in vitro models for predictive drug discovery and to create functional tissue-engineered implants for regeneration. Adult cardiomyocytes have a limited ability to proliferate, thus stem cells must be used as their source. The ability to generate cardiovascular lineages from human induced pluripotent stem cells and recent advances in 3D bioprinting, provide an unprecedented opportunity to establish human in vitro models of cardiovascular diseases (i.e. heart-on-a-chip models) as well as to develop autologous replacement left ventricle. 3D bioprinting allows precise layer-by-layer positioning of biomaterials (i.e. bioinks) and living cells, with spatial control of the placement of functional components to fabricate 3D functional living cardiac tissues with structural, biological, and mechanical properties that are very similar to those of native tissues. The 5-year goals of this research program are to: 1) fabricate and characterize 3D vascularized left ventricle using 3D bioprinting technology; and 2) fabricate and characterize 3D bioprinted heart-on-a-chip platforms. Therefore, we will develop and characterize a 3D bioprinted:1) sheet-like vascularized artificial left ventricle to accelerate regeneration; 2) ring-like structure as a 3D in vitro model for drug discovery and screening applications. The 3D bioprinted artificial vascularized left ventricle (sheet-like structures) will eventually be capable of synchronous contraction in response to electrical stimulation. In a more immediate term, the 3D bioprinted ring-like structures will provide high fidelity models for drug discovery and testing. This model has the potential to test cardiac toxicity with more precision and efficiency, due to the faithfully mimicking the hallmarks of human physiology. Given that cardiac toxicity is a major hurdle to bring novel drugs to market, our in vitro model can transform the drug development process. Furthermore, our in vitro model is compatible with precision medicine to test drugs in a more personalized environment and shed light to the underlying molecular mechanisms. Overall, it is foreseen that the outcome of this research program will constitute important steps towards providing human functional tissues for regeneration and in vitro modelling.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2021-03960
Name nom
Savoji, Houman
Department département
Biomedical Engineering
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2021
Award amount
28000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
3D Bioprinting of Cardiac Tissues
Keywords
3d bioprinting; bioinks; tissue engineering; biomaterials; cardivascular disease; in vitro characterization; mechanical characterization; stem cells; rapid prototyping; micro- & nano-fabrication
Application summary
Chronic cardiovascular diseases such as heart failure is increasing to epidemic levels, affecting 1 in 5 Canadians. The left ventricle has no significant ability to regenerate and the viable tissue remaining after myocardial infarction is often insufficient to maintain adequate cardiac output. Heart transplant is very often not an available or appropriate option. Thus, there is a pressing need for alternative intervention. The long-term goal of this research program is to develop and utilize advanced biofabrication techniques integrated with insights from developmental biology to build engineered 3D in vitro models for predictive drug discovery and to create functional tissue-engineered implants for regeneration. Adult cardiomyocytes have a limited ability to proliferate, thus stem cells must be used as their source. The ability to generate cardiovascular lineages from human induced pluripotent stem cells and recent advances in 3D bioprinting, provide an unprecedented opportunity to establish human in vitro models of cardiovascular diseases (i.e. heart-on-a-chip models) as well as to develop autologous replacement left ventricle. 3D bioprinting allows precise layer-by-layer positioning of biomaterials (i.e. bioinks) and living cells, with spatial control of the placement of functional components to fabricate 3D functional living cardiac tissues with structural, biological, and mechanical properties that are very similar to those of native tissues. The 5-year goals of this research program are to: 1) fabricate and characterize 3D vascularized left ventricle using 3D bioprinting technology; and 2) fabricate and characterize 3D bioprinted heart-on-a-chip platforms. Therefore, we will develop and characterize a 3D bioprinted:1) sheet-like vascularized artificial left ventricle to accelerate regeneration; 2) ring-like structure as a 3D in vitro model for drug discovery and screening applications. The 3D bioprinted artificial vascularized left ventricle (sheet-like structures) will eventually be capable of synchronous contraction in response to electrical stimulation. In a more immediate term, the 3D bioprinted ring-like structures will provide high fidelity models for drug discovery and testing. This model has the potential to test cardiac toxicity with more precision and efficiency, due to the faithfully mimicking the hallmarks of human physiology. Given that cardiac toxicity is a major hurdle to bring novel drugs to market, our in vitro model can transform the drug development process. Furthermore, our in vitro model is compatible with precision medicine to test drugs in a more personalized environment and shed light to the underlying molecular mechanisms. Overall, it is foreseen that the outcome of this research program will constitute important steps towards providing human functional tissues for regeneration and in vitro modelling.